WO2006050837A2 - Ophthalmic emulsions containing an immunosuppressive agent - Google Patents
Ophthalmic emulsions containing an immunosuppressive agent Download PDFInfo
- Publication number
- WO2006050837A2 WO2006050837A2 PCT/EP2005/011649 EP2005011649W WO2006050837A2 WO 2006050837 A2 WO2006050837 A2 WO 2006050837A2 EP 2005011649 W EP2005011649 W EP 2005011649W WO 2006050837 A2 WO2006050837 A2 WO 2006050837A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- emulsion
- oil
- anyone
- ophthalmic oil
- ophthalmic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- This invention relates to ophthalmic compositions, preferably ophthalmic emulsions, comprising an immunosuppressive agent as an active ingredient, in a specific vehicle containing oil and preferably tyloxapol, and being suitable for the treatment of eye conditions, particularly of dry eye diseases.
- Dry eye disease in the meaning of this invention, relates to any condition relating to ocular dryness and/or tear deficiency, including but not limited to conditions related to a pathological evaporation of fluid from the cornea surface, or conditions related to defective tear film, or more generally any corneal or conjunctive dryness, which can be due to insufficient production of tears, and the conditions resulting therefrom, such as corneal keratitis or corneal epithelium erosion. For example keratoconjunctivis sicca
- KCS atopic keratoconjunctivitis sicca
- VKC vernal keratoconjunctivitis
- Cyclosporines are a large class of peptide compounds having various pharmaceutical applications, such as immunosuppressant and anti-inflammatory applications. Cylosporines include cyclosporine A, B 7 C and D. The most widely investigated cyclosporin is cyclosporin A and cyclosporine A derivatives. Other common immunosuppressive agents are sirolimus or tacrolimus and their derivatives.
- Cyclosporine oil-in-water ophthalmic emulsions have been described, and among them the emulsions commercialized by Allergan under the trademark name Restasis ® (cyclosporine ophthalmic emulsion 0,05 %) .
- US 4,839,342 describe the use of cyclosporin for the treatment of immune keratoconjunctivis sicca (KCS) , and a method of increasing tear production for a tear-deficient eye, in particular directed to a patient suffering from a immune mediated dysfunction of lacrimal glands.
- the method disclosed in this patent includes administering cyclosporine, preferably cyclosporine A, with a pharmaceutical excipient being olive oil, arachis oil, castor oil or mineral oil.
- Shulin Ding and Orest Olejnik have published a poster in the AAPS annual meeting on November 3, 1997 ; this document relates to castor oil-based oil-in-water emulsions using 0.1 to 0.4% cyclosporine and having a weight ratio cyclosporine/oil of 0.08.
- This poster discloses that the concentration in cyclosporine A in the oil is optimized at the level of 7.4 % w/w which is below the solubility of the cyclosporine in the specific oil vehicle castor oil (10 % w/w) .
- WO2005/032577 describes a method for treating an eye of a human comprising administering an emulsion comprising less than 0.1 % cyclosporine and having a weight ratio cyclosporine/ castor oil of less than 0.08.
- An emulsion is a system consisting of two immiscible liquid phases, one of which, in fine droplets, is dispersed throughout the other, the system being stabilized by a third component, the emulsifying agent.
- Emulsions are inherently unstable, and emulsifiers are essential for both their initial formation and long-term stability.
- submicronic or nano-emulsions may appear transparent, and Brownian motion prevents sedimentation or creaming, hence offering increased stability.
- the instability of an emulsion will appear as phase separation due to creaming (density differences) , Ostwald ripening (disproportionation) flocculation (aggregation through interparticle collision) , and coalescence (fusion of separate droplets) .
- An important distinction is that flocculation is often reversible while coalescence is not.
- the process of droplet coalescence is the normal way in which an emulsion coarsens with time, i.e. the mean particle size of the droplet increases upon storage.
- a monomodal droplet population has the benefits of increased stability besides of the drug content uniformity which is essential in pharmaceutical applications for the administration of a correct drug dose.
- bioavailability means the percentage of drug that can be detected in the target ocular tissue after its administration. Detection of the drug can be accomplished pharmacodynamically (quantification of a biological response to the cyclosporine) or pharmacokinetically (quantification of actual drug concentration) .
- the emulsions of this invention comprise a combination of ingredients, allowing them to respond to both requirements of stability and bioavailability.
- this invention relates to ophthalmic emulsions which comprise colloid particles having an oily core surrounded by an interfacial film, said emulsion comprising at least one immunosuppressive agent, preferably selected from the group consisting of cyclosporine, sirolimus, tacrolimus, in a vehicle comprising an oil and tyloxapol .
- the amount of MCT is at least 50 % in weight of MCTby weight of the total oil content of the emulsion.
- the oil content of the emulsion is 100% MCT.
- the amount of MCT is from 0.5 to 4 %, preferably 0.9 to 3 %, more preferably . to 2 % w/w of the emulsion.
- the amount of tyloxapol is less than 1%, preferably comprised between 0.01 to 0.6% by weight of the total weight of the emulsion.
- MCT when combined with tyloxapol, provide even better results in terms of bioavailability of an immunosuppressive agent (Example 7) .
- the inventors have demonstrated a synergistic effect of tyloxapol and MCT in an ophthalmic emulsion of the invention containing an immunosuppressive agent, especially cyclosporine, sirolimus or tacrolimus.
- an immunosuppressive agent especially cyclosporine, sirolimus or tacrolimus.
- WO2005/032577 describes 1.25% castor-oil based emulsions for which increasing the amount of cyclosporine from 0.05% to 0.1% (and therefore the CsA/oil ratio from 0.04 to 0.08) does not improve the overall efficacy in treating dry eye disease.
- the Inventors have unexpectedly found that, when increasing the amount of immunosuppressive agent in the emulsions of the invention, an increasing amount of drug is transferred into the ocular target (see example 8) ; this means that the emulsions of the invention are not limited to a specific ratio of immunosuppressive agent/oil.
- the emulsions of the invention make it possible to increase the therapeutic amounts of drugs to be delivered of the target site, thus increasing the therapeutic values of the used immunosuppressive agent.
- the emulsion may further include any other suitable oily components, especially one or more oils selected from the group consisting of, olive, soy, corn, mineral, cottonseed, safflower, sesame.
- the emulsions are free of castor oil.
- the emulsion is anionic.
- the emulsion of the invention includes one or more components selected from the group consisting of phospholipids, cholic acid and its derivatives, metal carboxymethylcelluloses, metal carboxymethylhydroxyethylcelluloses, metal carboxymethylstarchs metal, carboxy methylhydroxyethylstarchs hydrolyzed polyacrylamides and polyacrylonitriles heparin gucoaminoglycans hyaluronic acid chondroitin sulphate, dermatan sulphate, peptides and polypeptides alginic acid, metal alginates homopolymers and copolymers of one or more of : acrylic and methacrylic acids metal acrylates and methacrylates vinylsulfonic acid, metal vinylsulfonate, amino acids, such as aspartic acid, glutamic acid and the like metal salts of amino acids p-styrenesulfonic acid metal p- styrenesulfonate, 2-methacrylo
- the emulsion is cationic.
- concentration of the cationic agent is comprised between 0.001 and 0.1% w/w, preferably between 0.002 and 0.05% w/w and still more preferably between 0.003 and 0.03% w/w.
- This second embodiment is particularly preferred, because it has been found that the cationic charge of the emulsion improves the bioavailability of the cyclosporine contained in the emulsion.
- the cationic cyclosporine-containing ophthalmic emulsion of the invention is an oil-in-water type emulsion, which comprises colloid particles having an oily core surrounded by an interfacial film, said emulsion comprising at least one cationic agent, at least one non ionic tensioactive, said emulsion having a positive zeta potential.
- the cationic ophthalmic emulsion of the invention meets the zeta potential stability Test A requirements as described below: Test A consists in measuring the stability of the emulsion zeta potential under thermal stress conditions.
- Glass vials (Type I) of 10ml effective capacity containing between 5-1OmI of emulsion and sealed under nitrogen atmosphere (without bubbling) are stored at 80 0 C.
- the value ⁇ A Z 7 ⁇ -Z 0 or Zi 5 I 1 -Z 0 is then calculated. For each measurement of the zeta potential, it is operated as follows:
- the zeta potential of the emulsion droplet surface is determined by electrophoretic mobility in an apparatus such as a Malvern Zetasizer 2000 (Malvern Instruments, UK) equipped with suitable software and calibrated with the supplied standard.
- the emulsion is diluted in double distilled water if needed in order to obtain the scattering intensity allowing optimal particle detection.
- the sample count rate should be between 100 to 1000 KCps, in homodyne detection (if heterodyne detection is used, the contribution of the reference beam should be deduced) .
- Three consecutive measurements are performed at 25°C using a constant cell drive of 15OmV.
- the electrophoretic mobility is converted into zeta potential values through the Smoluchowsky equation, using the dielectric constants and viscosity of water. The measured value corresponds to the average of the 3 obtained values.
- ⁇ A is less than the standard error of measurements, preferably less than 1OmV, and even more preferably less than 5mV.
- the emulsion of the invention contains cyclosporine A.
- the emulsion of the invention contains from 0.01 to 0.4 % w/w, preferably 0.05 to 0.3 % of immunosuppressive agent, preferably cyclosporine, more preferably cyclosporine A.
- the emulsion comprises an amount of tacrolimus of 0.01 to 0.3 % w/w, preferably 0.05 to 0.2% w/w of the emulsion.
- the emulsion comprises an amount of sirolimus of 0.01 to 0.3 % w/w, preferably 0.05 to 0.2% w/w of the emulsion.
- the weight ratio of immunosuppressive agent to oil is from 0.0125 to 0.1.
- the emulsion of the weight ratio of immunosuppressive agent to oil is from 0.083 to 0.1.
- the emulsion of the weight ratio of immunosuppressive agent to oil is from 0.0125 to 0.05.
- the emulsion of the invention is submicronic, and in a very preferred embodiment, monomodal submicronic, which means that the colloid particles of the invention are very homogeneous in their size equal or less than 1 ⁇ m, in that they have a droplet size polydispersity index close to 0.2, generally between 0.1 and 0.15. The calculation of the polydispersity index is defined in the ISO standard document 13321 :1996 E.
- colloid particles of the emulsion of the invention have an average particle size of equal or less than 1 ⁇ m, advantageously equal or less than 300 nm, more advantageously in the range of 100 to 250 nm.
- the emulsions of the invention are cationic submicronic emulsions, and do not contain any substances capable of generating a sufficient amount of negative charge for affecting the positive zeta potential of the emulsion.
- the emulsion does not contain phospholipids.
- the invention also relates to a process of preparation of the emulsions containing at least one immunosuppressive agent, preferably chosen in the group consisting of cyclosporine, preferably cyclosporine A, sirolimus or tacrolimus and MCT and tyloxapol according to the invention, comprising one step of shear mixing followed by a high pressure homogenization.
- immunosuppressive agent preferably chosen in the group consisting of cyclosporine, preferably cyclosporine A, sirolimus or tacrolimus and MCT and tyloxapol according to the invention, comprising one step of shear mixing followed by a high pressure homogenization.
- Cremophor Cremophor EL (BASF, Germany) Lipoid E80 (Lipoid GMBH, Germany)
- Lutrol F68 Lutrol F68 (BASF, Germany)
- the oily phase components are successively weighed and then stirred under a slight heating until a limpid and slightly viscous phase is obtained.
- Aqueous phase components are successively weighed and then magnetically stirred under a slight heating until a transparent, limpid and fluid phase is obtained. Both phases are heated and the coarse emulsion is formed by rapid addition of the aqueous phase in the oily phase and then rapidly heated to 75 0 C.
- the emulsion is white and slightly transparent.
- the emulsion droplet size is then decreased by high shear mixing by using for example a POLYTRON PT 6100, followed by its cooling down.
- Final emulsion is obtained by high pressure homogenization in suitable equipment such as microfluidizer (C5, Avestin) using several continuous cycles.
- Final emulsion is milky and very fluid.
- the emulsion temperature is then decreased to 25°C, its pH was measured and then adjusted to 6.0, 7.0, 8.0 using a 0.1 M HCl or 0.1 M NaOH solution.
- Sterilization can be done by autoclave 20 minutes at 121 0 C or by filtration through a 0.22 urn filter.
- Example 2 Characterization of the emulsions of this invention
- the mean particle size of the emulsions droplets is determined by quasi-elastic light scattering after dilution in water using for example a High Performance Particle Sizer (Malvern Instruments, UK) . This instrumentation is also used to determine the polydispersity index.
- the electrophoretic mobility is measured at 25 0 C in an appropriate apparatus such as Malvern Zetasizer 2000 (Malvern Instruments, UK) following a 1:200 dilution in double distilled water and converted into zeta potential through the Smoluchowski equation.
- CsA in the emulsion is determined by a validated HPLC-UV method.
- Example 3 Compositions of this invention containing CsA/oil/Tyloxapol
- MCT/Tyloxapol-based emulsions of CsA produced by the process of the invention including a shear mixing step followed by a high pressure homogenisation step are stable following preparation and for at least two weeks at 8O 0 C.
- Example 5 Comparative example - Compositions containing CsA/castor oil
- Example 6 Stability of emulsions containing CsA/castor oil
- Percentages indicate the relative populations as measured by scattered light.
- Castor oil-emulsions of CsA produced by homogenisation techniques as described above are not stable following preparation or after one week at 8O 0 C.
- Example 7 Efficacy of emulsions of this invention as evaluated by their pharmacokinetic parameters.
- the emulsions described in this invention show tissue concentrations at least as good as the castor oil-based marketed emulsion Restasis ® .
- Example 8 Impact of the CsA/oil ratio in the emulsions of this invention on their efficacy as evaluated by their pharmacokinetic parameters.
- One hundred and forty-four (144) pigmented rabbits from the HYRNZ104 strain were randomly divided into three (3) treatment groups of forty eight (48) animals, .each group being sub ⁇ divided into eight (8) subgroups of six (6) animals corresponding to eight (8) time-points (0.33, 0.66, 1, 2, 4, 8, 12 and 24 hrs) .
- the animals received a single instillation into right eyes of the above described EM048, EM050 or EM053 ( 0 . 025 , 0 . 05 and 0 . 1% w/w CsA in 2% MCT emulsions) .
- animals were euthanized and the conj unctiva was sampled .
- Content of CsA was determined by HPLC-MS .
- the area under the curve (AUC) indicating the animal exposure to the compound was calculated using the trapezoidal rule .
- the emulsions described in this invention show a linear correlation between the CsA/oil ratio and the conjunctival concentration. As the clinical efficacy is correlated to the CsA concentration, it can be assumed that this particular vehicle will provide increasing therapeutic value for rising amounts of CsA
- Example 9 Ocular tolerance of the emulsions of this invention
- the aim of this study was to determine the ocular tolerance of the emulsions of this invention (EM048, EM050 and EMO53 ; see composition in previous examples) after multiples daily ocular topical administrations for 28 consecutive days into the right eye of albino rabbits.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077006312A KR101319772B1 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressive agent |
JP2007539521A JP5008571B2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsion containing immunosuppressant |
DK05802097.5T DK1809238T3 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressant |
AU2005304034A AU2005304034B2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressive agent |
DE602005010733T DE602005010733D1 (en) | 2004-11-09 | 2005-10-10 | OPHTHALMIC EMULSION WITH AN IMMUNOSUP PRESSIVE MEDIUM |
MX2007003045A MX2007003045A (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressive agent. |
EP05802097A EP1809238B1 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressive agent |
CA2578176A CA2578176C (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressive agent |
US11/665,066 US8298569B2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressive agent |
IL181446A IL181446A (en) | 2004-11-09 | 2007-02-20 | Ophthalmic emulsions containing an immunosuppressive agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04292645.1 | 2004-11-09 | ||
EP04292645A EP1655021B1 (en) | 2004-11-09 | 2004-11-09 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
US10/991,346 | 2004-11-18 | ||
US10/991,346 US8298568B2 (en) | 2004-11-09 | 2004-11-18 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006050837A2 true WO2006050837A2 (en) | 2006-05-18 |
WO2006050837A3 WO2006050837A3 (en) | 2006-11-16 |
Family
ID=35466464
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/011650 WO2006050838A2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
PCT/EP2005/011649 WO2006050837A2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing an immunosuppressive agent |
PCT/EP2005/011648 WO2006050836A2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing prostaglandins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/011650 WO2006050838A2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/011648 WO2006050836A2 (en) | 2004-11-09 | 2005-10-10 | Ophthalmic emulsions containing prostaglandins |
Country Status (7)
Country | Link |
---|---|
EP (4) | EP1809237B1 (en) |
JP (2) | JP5122969B2 (en) |
KR (2) | KR101319772B1 (en) |
AU (2) | AU2005304035B2 (en) |
CA (2) | CA2586074C (en) |
DK (1) | DK1809238T3 (en) |
WO (3) | WO2006050838A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008014200A2 (en) * | 2006-07-25 | 2008-01-31 | Allergan, Inc. | Cyclosporin compositions |
JP2014028865A (en) * | 2013-11-11 | 2014-02-13 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
US8678184B2 (en) | 2009-12-03 | 2014-03-25 | Novartis Ag | Methods for producing vaccine adjuvants |
US8778275B2 (en) | 2009-12-03 | 2014-07-15 | Novartis Ag | Methods for producing vaccine adjuvants |
US8871816B2 (en) | 2009-12-03 | 2014-10-28 | Novartis Ag | Methods for producing vaccine adjuvants |
US8895629B2 (en) | 2009-12-03 | 2014-11-25 | Novartis Ag | Circulation of components during homogenization of emulsions |
US9364461B2 (en) | 2006-12-21 | 2016-06-14 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
AU2016203191B2 (en) * | 2006-07-25 | 2018-03-01 | Allergan, Inc. | Cyclosporin compositions |
USRE46906E1 (en) | 2009-12-03 | 2018-06-26 | Novartis Ag | Methods for producing vaccine adjuvants |
US10213383B2 (en) | 2009-12-03 | 2019-02-26 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
EP2380558B2 (en) † | 2009-12-03 | 2019-10-16 | Novartis AG | Manufacturing of an emulsion under arrangement of interaction and back pressure chamber for microfluidization |
US10835517B2 (en) | 2017-12-15 | 2020-11-17 | Tarsus Pharmaceuticals, Inc. | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
US11612658B2 (en) | 2006-07-28 | 2023-03-28 | Santen Sas | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE412400T1 (en) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | OIL-IN-WATER EMULSION WITH LOW CATIONIC AGENT CONCENTRATION AND POSITIVE ZETA POTENTIAL |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
EP2322183B1 (en) | 2006-06-01 | 2014-10-22 | Santen SAS | Use of prodrugs for ocular intravitreous administration |
JP4411440B2 (en) * | 2006-06-02 | 2010-02-10 | 国立大学法人 筑波大学 | Particle characteristic measuring apparatus and particle characteristic measuring method |
AU2014201978B2 (en) * | 2006-07-28 | 2016-03-10 | Santen Sas | Compositions containing quaternary ammonium compounds |
PT1891939E (en) * | 2006-07-28 | 2013-10-07 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
CA2676919C (en) * | 2007-01-31 | 2013-01-29 | Allergan, Inc. | Novel biomaterials for ocular drug delivery and a method for making and using same |
US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
EP1985298A1 (en) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
EP2008651A1 (en) | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
AU2008280437B2 (en) * | 2007-07-26 | 2012-11-29 | Azad Pharma Ag | Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions |
MX340897B (en) * | 2007-10-02 | 2016-07-29 | Theranos Inc | Modular point-of-care devices and uses thereof. |
CN101835473B (en) * | 2007-10-16 | 2012-12-05 | 太阳医药高级研发有限公司 | Novel ophthalmic compositions containing latanoprost |
ES2719226T3 (en) * | 2007-12-04 | 2019-07-09 | Santen Sas | Compositions comprising corticosteroid prodrugs such as dexamethasone palmitate for the treatment of eye disorders |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
EP2228057A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Cationic oil-in-water emulsions containing prostaglandins and uses thereof |
US9480645B2 (en) | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
US20100305046A1 (en) | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
US20100303915A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Therapeutic opthalmic emulsions |
EP2308468A1 (en) * | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
EP2498784A2 (en) * | 2009-11-09 | 2012-09-19 | Allergan, Inc. | Compositions for enhancing hair growth |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
IT1404931B1 (en) | 2010-06-11 | 2013-12-09 | Medivis S R L | OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES. |
US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
RU2639472C2 (en) | 2011-03-14 | 2017-12-21 | Драг Деливери Солюшнз Лимитед | Ophthalmic composition |
WO2013022238A2 (en) * | 2011-08-05 | 2013-02-14 | (주)제노텍 | Tricyclic glycosylated derivative compound, a production method therefor, and an immunosuppressant pharmaceutical composition comprising a tacrolimus glycosylation derivative |
KR101318151B1 (en) * | 2011-09-26 | 2013-10-15 | (주) 제노텍 | Pharmaceutical composition for immunosupression containing glycosylated tacrolimus derivatives |
US9089529B2 (en) | 2011-10-25 | 2015-07-28 | Prothena Therapeutics Limited | Antibody formulations and methods |
CA2900840C (en) * | 2013-03-14 | 2023-03-28 | Panoptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
WO2015123631A1 (en) * | 2014-02-14 | 2015-08-20 | Jingjun Huang | Compositions of nanoemulsion delivery systems |
EP2937076B1 (en) * | 2014-04-25 | 2019-09-11 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Eye drops containing prostaglandin and tyloxapol |
US9532944B2 (en) * | 2014-10-20 | 2017-01-03 | Oyster Point Pharma, Inc. | Methods of improving ocular discomfort |
US20180028667A1 (en) * | 2014-12-10 | 2018-02-01 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid agent |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
AU2016215182B2 (en) | 2015-02-06 | 2019-09-12 | R. P. Scherer Technologies, Llc | Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations |
CA3066408A1 (en) | 2017-06-10 | 2018-12-13 | Eyenovia, Inc. | Methods and devices for handling a fluid and delivering the fluid to the eye |
US20210128534A1 (en) * | 2018-02-26 | 2021-05-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Drug delivery systems |
EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
CN111212642A (en) * | 2018-08-29 | 2020-05-29 | 奥古根有限公司 | Ophthalmic compositions and methods of use |
WO2020044308A1 (en) * | 2018-08-30 | 2020-03-05 | Sabic Global Technologies B.V. | High yield stabilized colloidal particle assemblies |
EP3970692A1 (en) | 2020-09-18 | 2022-03-23 | Omnivision GmbH | Lipid-based ophthalmic composition for the treatment of dry eye |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053405A1 (en) * | 2001-11-01 | 2003-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and composition for dry eye treatment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0818989B2 (en) * | 1984-01-12 | 1996-02-28 | 株式会社ミドリ十字 | A method for stabilizing prostaglandins in fat emulsions. |
US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
JP2602964B2 (en) * | 1989-10-16 | 1997-04-23 | 裕 水島 | Prostaglandin analogs and their fat emulsions |
IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
DE69328368T2 (en) * | 1992-08-28 | 2000-08-10 | Pharmos Corp., New York | EMULSIONS IN THE SUBMICRON AREA AS A VEHICLE FOR DRUG ADMINISTRATION ON THE EYE |
IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
ES2094688B1 (en) * | 1994-08-08 | 1997-08-01 | Cusi Lab | MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION. |
US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
JP3410364B2 (en) * | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | Difluprednate-containing composition |
EP0878197B1 (en) | 1997-05-14 | 2002-08-21 | Senju Pharmaceutical Co., Ltd. | Compositions containing difluprednate |
US6656460B2 (en) | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
KR100446960B1 (en) * | 2001-12-04 | 2004-09-01 | 김종국 | Composition of thermosensitive emulsion for external use of prostaglandin E1 |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
ATE442146T1 (en) | 2003-11-07 | 2009-09-15 | Senju Pharma Co | PHARMACEUTICAL COMPOSITION CONTAINING PROSTAGLANDIN |
ATE439123T1 (en) | 2004-07-02 | 2009-08-15 | Novagali Pharma Sa | USE OF EMULSIONS FOR INTRA- AND PERIOCULAR INJECTION |
-
2005
- 2005-10-10 EP EP05795930A patent/EP1809237B1/en active Active
- 2005-10-10 EP EP05802097A patent/EP1809238B1/en active Active
- 2005-10-10 JP JP2007539522A patent/JP5122969B2/en active Active
- 2005-10-10 JP JP2007539521A patent/JP5008571B2/en active Active
- 2005-10-10 AU AU2005304035A patent/AU2005304035B2/en active Active
- 2005-10-10 WO PCT/EP2005/011650 patent/WO2006050838A2/en active Application Filing
- 2005-10-10 CA CA2586074A patent/CA2586074C/en active Active
- 2005-10-10 EP EP08102553A patent/EP1929996B1/en active Active
- 2005-10-10 DK DK05802097.5T patent/DK1809238T3/en active
- 2005-10-10 WO PCT/EP2005/011649 patent/WO2006050837A2/en active Application Filing
- 2005-10-10 KR KR1020077006312A patent/KR101319772B1/en active IP Right Grant
- 2005-10-10 EP EP05800012A patent/EP1827373B1/en active Active
- 2005-10-10 KR KR1020077010520A patent/KR101333923B1/en active IP Right Grant
- 2005-10-10 AU AU2005304034A patent/AU2005304034B2/en active Active
- 2005-10-10 WO PCT/EP2005/011648 patent/WO2006050836A2/en active Application Filing
- 2005-10-10 CA CA2578176A patent/CA2578176C/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053405A1 (en) * | 2001-11-01 | 2003-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and composition for dry eye treatment |
Non-Patent Citations (2)
Title |
---|
DING S ET AL: "CYCLOSPORINE OPHTHALMIC O/W EMULSION: FORMULATION AND EMULSION CHARACTERIZATION" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 14, no. 11, SUPPL, November 1997 (1997-11), page S41, XP008005736 ISSN: 0724-8741 cited in the application * |
TAMILVANAN S ET AL: "The potential of lipid emulsion for ocular delivery of lipophilic drugs" EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 58, no. 2, 1 June 2004 (2004-06-01), pages 357-368, XP004526318 ISSN: 0939-6411 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008014200A3 (en) * | 2006-07-25 | 2008-08-28 | Allergan Inc | Cyclosporin compositions |
AU2007276815B2 (en) * | 2006-07-25 | 2013-05-09 | Allergan, Inc. | Cyclosporin compositions |
JP2014015471A (en) * | 2006-07-25 | 2014-01-30 | Allergan Inc | Cyclosporin compositions |
AU2016203191B2 (en) * | 2006-07-25 | 2018-03-01 | Allergan, Inc. | Cyclosporin compositions |
WO2008014200A2 (en) * | 2006-07-25 | 2008-01-31 | Allergan, Inc. | Cyclosporin compositions |
US9561178B2 (en) | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
US11612658B2 (en) | 2006-07-28 | 2023-03-28 | Santen Sas | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same |
US9364461B2 (en) | 2006-12-21 | 2016-06-14 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
US9700616B2 (en) | 2009-12-03 | 2017-07-11 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
EP2380558B2 (en) † | 2009-12-03 | 2019-10-16 | Novartis AG | Manufacturing of an emulsion under arrangement of interaction and back pressure chamber for microfluidization |
US9463240B2 (en) | 2009-12-03 | 2016-10-11 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
US8871816B2 (en) | 2009-12-03 | 2014-10-28 | Novartis Ag | Methods for producing vaccine adjuvants |
US11141376B2 (en) | 2009-12-03 | 2021-10-12 | Novartis Ag | Circulation of components during microfluidization and/or homogenization of emulsions |
USRE46441E1 (en) | 2009-12-03 | 2017-06-20 | Novartis Ag | Circulation of components during homogenization of emulsions |
US8778275B2 (en) | 2009-12-03 | 2014-07-15 | Novartis Ag | Methods for producing vaccine adjuvants |
US9750690B2 (en) | 2009-12-03 | 2017-09-05 | Novartis Ag | Circulation of components during microfluidization and/or homogenization of emulsions |
US8678184B2 (en) | 2009-12-03 | 2014-03-25 | Novartis Ag | Methods for producing vaccine adjuvants |
USRE46906E1 (en) | 2009-12-03 | 2018-06-26 | Novartis Ag | Methods for producing vaccine adjuvants |
US10213383B2 (en) | 2009-12-03 | 2019-02-26 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
US8895629B2 (en) | 2009-12-03 | 2014-11-25 | Novartis Ag | Circulation of components during homogenization of emulsions |
US10463615B2 (en) | 2009-12-03 | 2019-11-05 | Novartis Ag | Circulation of components during microfluidization and/or homogenization of emulsions |
US10799454B2 (en) | 2009-12-03 | 2020-10-13 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
JP2014028865A (en) * | 2013-11-11 | 2014-02-13 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
US10835517B2 (en) | 2017-12-15 | 2020-11-17 | Tarsus Pharmaceuticals, Inc. | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
US11197847B2 (en) | 2017-12-15 | 2021-12-14 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
US11690827B2 (en) | 2017-12-15 | 2023-07-04 | Tarsus Pharmaceuticals, Inc. | Methods for treating ocular Demodex using lotilaner formulations |
US11690826B2 (en) | 2017-12-15 | 2023-07-04 | Tarsus Pharmaceuticals, Inc. | Methods for treating demodex blepharitis using lotilaner formulations |
US11752137B2 (en) | 2017-12-15 | 2023-09-12 | Tarsus Pharmaceuticals, Inc. | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations |
Also Published As
Publication number | Publication date |
---|---|
EP1929996A2 (en) | 2008-06-11 |
EP1827373B1 (en) | 2008-12-03 |
JP5008571B2 (en) | 2012-08-22 |
JP5122969B2 (en) | 2013-01-16 |
AU2005304034B2 (en) | 2012-02-16 |
AU2005304035B2 (en) | 2010-07-22 |
AU2005304034A1 (en) | 2006-05-18 |
WO2006050836A3 (en) | 2007-07-12 |
JP2008518992A (en) | 2008-06-05 |
CA2586074A1 (en) | 2006-05-18 |
AU2005304035A1 (en) | 2006-05-18 |
KR101333923B1 (en) | 2013-11-27 |
EP1827373A2 (en) | 2007-09-05 |
DK1809238T3 (en) | 2010-01-25 |
CA2578176C (en) | 2013-09-24 |
EP1929996B1 (en) | 2011-02-16 |
EP1809238B1 (en) | 2008-10-29 |
WO2006050837A3 (en) | 2006-11-16 |
EP1809237B1 (en) | 2008-12-31 |
KR20070083573A (en) | 2007-08-24 |
KR101319772B1 (en) | 2013-10-23 |
KR20070084107A (en) | 2007-08-24 |
EP1929996A3 (en) | 2009-05-20 |
EP1809238A2 (en) | 2007-07-25 |
CA2578176A1 (en) | 2006-05-18 |
WO2006050836A2 (en) | 2006-05-18 |
WO2006050838A3 (en) | 2006-11-16 |
EP1809237A2 (en) | 2007-07-25 |
CA2586074C (en) | 2013-07-23 |
JP2008518993A (en) | 2008-06-05 |
WO2006050838A2 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2578176C (en) | Ophthalmic emulsions containing an immunosuppressive agent | |
US8298569B2 (en) | Ophthalmic emulsions containing an immunosuppressive agent | |
Tamilvanan et al. | The potential of lipid emulsion for ocular delivery of lipophilic drugs | |
Hegde et al. | Microemulsion: new insights into the ocular drug delivery | |
JP5986296B2 (en) | Non-irritating nanoemulsion eye drop composition containing cyclosporine | |
EP2978409B1 (en) | Ophthalmic composition, method for preparing the same, and use of the same | |
JP2020117551A (en) | Methods of diagnosing and treating dry eye syndrome and compositions for treating human eye | |
EP2968139B1 (en) | Microemulsion topical delivery platform | |
JPH05186333A (en) | Ophthalmic composition | |
Cardoso et al. | In situ gelling microemulsion for topical ocular delivery of moxifloxacin and betamethasone | |
US10987304B2 (en) | Ocular delivery of drugs | |
CN112516084A (en) | In situ gel containing cyclosporine micelles as sustained release ophthalmic drug delivery system | |
AU2012202829B2 (en) | Ophthalmic emulsions containing an immunosuppressive agent | |
KR20150000405A (en) | Oil-in-Water Emulsion Composition of Water-Insoluble Pharmaceutical Compounds and Method for Preparing the Same | |
Mehetre et al. | Rationalized approach for formulation and optimization of ebastine microemulsion using design expert for solubility enhancement | |
Ajmeera et al. | Development of nanoemulsion to improve the ocular bioavailability and patient compliance in postoperative treatment using indomethacin | |
Bodkhe et al. | Ophthalmic Microemulsion: Formulation Design and Process Optimization | |
Lallemand et al. | Emulsions for topical eye delivery: state of the art and future perspectives | |
EP3970692A1 (en) | Lipid-based ophthalmic composition for the treatment of dry eye | |
Varner | Development of an Ophthalmic Nanoemulsion Containing Δ9-Tetrahydrocannabinol-Valine-Hemisuccinate (THC-VHS; NB1111) for Management of Glaucoma | |
Chirlekar et al. | FUNDAMENTAL ASPECTS IN THE DEVELOPMENT OF MICROEMULSION SYSTEMS CONTAINING AMPHOTERICIN B FOR OPHTHALMIC USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005802097 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 181446 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005304034 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2578176 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580030069.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/003045 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2005304034 Country of ref document: AU Date of ref document: 20051010 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005304034 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077006312 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11665066 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007539521 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1664/KOLNP/2007 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005802097 Country of ref document: EP |